Moleculin Biotech, Inc. — Director's Dealing 2017

Aug 19, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2017-08-16

Reporting Person: KLEMP WALTER V (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-16	Common Stock	S	100000	$1.703	Disposed	967724	Direct

Footnotes

F1: The reporting person entered into a private sale agreement for the shares of common stock set forth in the table. The 12,000 shares of common stock purchased by the reporting person on May 11, 2017 are a matching transaction under Section 16 of the Securities Exchange Act of 1934 with 12,000 shares of common stock sold by the reporting person as set forth in the table above. In Accordance with Section 16, the reporting person will disgorge to the issuer an aggregate short-swing profit of $10,716.

F2: In addition to the shares held directly by the reporting person, the reporting person is the majority shareholder and control person of Annamed, Inc. Annamed, Inc. holds 1,425,000 shares of Issuer common stock. The Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by Annamed, Inc.